pI: 8.2579 |
Length (AA): 1189 |
MW (Da): 135583 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_133787)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_39765 | Protein kinase domain containing protein |
Caenorhabditis elegans | CELE_W03G1.6 | Protein PIG-1, isoform B |
Echinococcus granulosus | EgrG_000500200 | maternal embryonic leucine zipper kinase |
Echinococcus multilocularis | EmuJ_000500200 | maternal embryonic leucine zipper kinase |
Homo sapiens | ENSG00000165304 | maternal embryonic leucine zipper kinase |
Loa Loa (eye worm) | LOAG_00732 | CAMK/CAMKL/MELK protein kinase |
Mus musculus | ENSMUSG00000035683 | maternal embryonic leucine zipper kinase |
Schistosoma japonicum | Sjp_0150020 | gsx family homeobox protein; serine/threonine kinase |
Schistosoma japonicum | Sjp_0012410 | ko:K08799 maternal embryonic leucine zipper kinase, putative |
Schistosoma mansoni | Smp_166150 | serine/threonine kinase |
Schmidtea mediterranea | mk4.001893.00 | |
Trichomonas vaginalis | TVAG_174020 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_119830 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_045990 | CAMK family protein kinase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
CELE_W03G1.6 | Caenorhabditis elegans | larval lethal | wormbase |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | maternal embryonic leucine zipper kinase | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 29.4% | 286 aa | Compounds | References |
Rattus norvegicus | Serine/threonine-protein kinase pim-3 | 326 aa | 26.1% | 291 aa | Compounds | References |
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 26.7% | 288 aa | Compounds | References |
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 27.3% | 304 aa | Compounds | References |